LOS ANGELES--(BUSINESS WIRE)--Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that a paper authored by its Senior Vice President and Chief Medical Officer Omar S. Manejwala titled “Anxiety Disorders: Scope and Clinical Considerations” has been published in the peer-reviewed Journal of Managed Care Medicine.
In the paper, Dr. Manejwala writes, “Despite the widespread availability of multiple treatments for anxiety disorders and substantial morbidity of untreated illness, the vast majority of individuals with anxiety disorders remain untreated. A National Comorbidity Study Replication found that only 36.9 percent of individuals with anxiety disorder received any treatment in the past 12 months and delay among those who eventually make treatment contact ranges from nine to 23 years. Fewer than one-third of the cases received minimally adequate care.”
Commenting on the paper, Dr. Manejwala stated, “Anxiety disorders are the most common psychiatric conditions—and they are responsible for over $20 billion in annual costs related to worsening medical conditions. Effective treatments exist but engagement remains poor, so most people cannot get the care they so desperately need to recover. Catasys’ mission is to solve for this needless suffering by uniquely engaging people in a program that produces durable behavior change, significantly improving quality of life while reducing healthcare costs.”
Catasys identifies, engages and treats health plan members with unaddressed behavioral conditions such as anxiety that worsen their chronic medical diseases. Today these members, who represent 1% to 3% of the health plan population, drive an anticipated average of 20% to 30% of all medical expenditures, and that number appears to be growing over time. These care avoidant members are identified through predictive analytics, engaged through multi-modal outreach and relationship-building, and enrolled in the OnTrak program. OnTrak is an integrated, 52-week program that delivers AI fingerprinted, evidence-based treatments. The result is better health and improved quality of life for the member, and an approximately 50% reduction in paid claims from the year prior to enrollment that is durable over a two-year period.
About Catasys, Inc.
Catasys, Inc. harnesses proprietary big data predictive analytics, artificial intelligence and telehealth, combined with human intervention, to deliver improved member health and cost savings to health plans through integrated technology enabled treatment solutions. It is our mission to provide access to affordable and effective care, thereby improving health and reducing cost of care for people who suffer from the medical consequences of behavioral health conditions; helping these people and their families achieve and maintain better lives.
Catasys' OnTrak solution--contracted with a growing number of national and regional health plans--is designed to treat members with behavioral conditions that cause or exacerbate co-existing medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure, which result in high medical costs.
Catasys has a unique ability to engage these members, who do not otherwise seek behavioral healthcare, leveraging proprietary enrollment capabilities built on deep insights into the drivers of care avoidance matched with data driven engagement technologies.
OnTrak integrates evidence-based medical and psychosocial interventions along with care coaching in a 52-week outpatient solution. The program is currently improving member health and, at the same time, is demonstrating reduced inpatient and emergency room utilization, driving a more than 50 percent reduction in total health insurers' costs for enrolled members. OnTrak is available to members of several leading health plans in California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, Nebraska, New Jersey, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin.